Main clinical and laboratory data of the 2 patients with the highest anti-tPA antibody levels
Characteristics . | Patient no. 1 . | Patient no. 2 . |
|---|---|---|
| Sex | Female | Female |
| Age, y | 37 | 46 |
| Clinical history | 3 pregnancy losses | Ischemic stroke |
| Lupus anticoagulant | + | + |
| ACLAs, GPL units | 13.5 | 180 |
| ACLAs, MPL units | 3.8 | NA |
| Anti-tPA antibodies, U/mL | 130 | 100 |
| tPA antigen, ng/mL | 17.2 | 7 |
| tPA activity, IU/mL | 0.12 | 0.10 |
| PAI activity, IU/mL | 0.1 | 0.2 |
Characteristics . | Patient no. 1 . | Patient no. 2 . |
|---|---|---|
| Sex | Female | Female |
| Age, y | 37 | 46 |
| Clinical history | 3 pregnancy losses | Ischemic stroke |
| Lupus anticoagulant | + | + |
| ACLAs, GPL units | 13.5 | 180 |
| ACLAs, MPL units | 3.8 | NA |
| Anti-tPA antibodies, U/mL | 130 | 100 |
| tPA antigen, ng/mL | 17.2 | 7 |
| tPA activity, IU/mL | 0.12 | 0.10 |
| PAI activity, IU/mL | 0.1 | 0.2 |
Normal ranges: anticardiolipin antibodies, GPL less than 21, MPL less than 21; anti-tPA antibodies, less than 11 U/mL; tPA antigen, 1.7 to 12.3 ng/mL; tPA activity, 0.20-2.00 IU/mL; PAI activity levels, 0.1 to 18.4 IU/mL.
NA indicates not available.